The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Olmesartan Hydrochlorothiazide Rowex 20 mg/25 mg film-coated tablets

20 mg/25 milligram(s) Film-coated tablet

Rowex LtdPA0711/240/002

Main Information

Trade NameOlmesartan Hydrochlorothiazide Rowex 20 mg/25 mg film-coated tablets
Active SubstancesOlmesartan medoxomil
Strength20 mg/25 milligram(s)
Dosage FormFilm-coated tablet
Licence HolderRowex Ltd
Licence NumberPA0711/240/002

Group Information

ATC CodeC09DA Angiotensin II antagonists and diuretics


Withdrawn Date15/04/2021
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0106-163-003
Interchangeable List DocumentPDF of Interchangeable List
« Back